

## Genomic DNA Extracts, PCR Quantification Standards, 10CFU™ and 100CFU™ Sensitivity Standards

## Genomic & Microbial Reference Materials

- ✓ Genomic DNA extracts of defined microorganisms for specificity testing in conventional and qPCR
- ✓ PCR quantification standards of mycoplasma and bacterial genomic DNA for applications in conventional and qPCR
- ✓ 10CFU™ and 100CFU™ Sensitivity Standards for validating robustness and sensitivity of molecular methods for mycoplasma detection as required by the *European Pharmacopoeia*, Chapter 2.6.7, USP <1071> and by the *Japanese Pharmacopoeia*, Chapter G3

Distributed by:

**CliniSciences Group**





# Genomic DNA Extracts

## Background & Description

- Conventional and qPCR
- Specificity testing

These preparations contain genomic DNA extracted from defined microorganisms at low passage, extracted by subsequent column absorption methods. The DNA extract is then partially sequenced to confirm identity and titrated.

## Ordering Information

51-0116	<i>Acholeplasma laidlawii</i>	51-3361	Methicilin-resistant <i>Staphylococcus aureus</i> (MRSA)
2127-30007	<i>Acinetobacter bamanii</i>	2134-30164	<i>Morganella morganii</i>
2128-30187	<i>Aeromonas hydrophila</i>	51-0030	<i>Micrococcus luteus</i>
2101-00819	<i>Aspergillus fumigatus</i>	51-0129	<i>Mycoplasma arginini</i>
51-0031	<i>Bacillus cereus</i>	51-0162	<i>Mycoplasma arthritidis</i>
51-0010	<i>Bacillus subtilis</i>	51-0117	<i>Mycoplasma fermentans</i>
2129-02046	<i>Bacillus thuringiensis</i>	51-0115	<i>Mycoplasma gallisepticum</i>
51-5571	<i>Bordetella pertussis</i>	51-0195	<i>Mycoplasma genitalium</i>
2130-07288	<i>Burkholderia cepacia</i>	51-0111	<i>Mycoplasma hominis</i>
2102-04688	<i>Campylobacter jejuni</i>	51-0130	<i>Mycoplasma hyorhinis</i>
51-1386	<i>Candida albicans</i>	51-0112	<i>Mycoplasma orale</i>
2103-11226	<i>Candida glabrata</i>	51-1746	<i>Mycoplasma penetrans</i>
2104-11947	<i>Candida guilliermondii</i>	51-0119	<i>Mycoplasma pneumoniae</i>
2105-70624	<i>Candida haemulonii</i>	51-0124	<i>Mycoplasma synoviae</i>
2106-30039	<i>Citrobacter freundii</i>	2135-10036	<i>Neisseria meningitidis</i>
2125-90874	<i>Candida tropicalis</i>	2136-13387	<i>Proteus vulgaris</i>
2107-04595	<i>Citrobacter koseri</i>	51-0071	<i>Pseudomonas aeruginosa</i>
51-0792	<i>Clostridium acetobutylicum</i>	2116-04479	<i>Proteus mirabilis</i>
2108-00756	<i>Clostridium perfringens</i>	51-7058	<i>Salmonella enterica</i>
51-0053	<i>Enterobacter aerogenes</i>	2117-30121	<i>Serratia marcescens</i>
2110-30054	<i>Enterobacter cloacae</i>	2137-04782	<i>Shigella flexneri</i>
2111-20680	<i>Enterococcus casseliflavus</i>	2138-05570	<i>Shigella sonnei</i>
2112-30633	<i>Enterococcus durans</i>	51-0164	<i>Spiroplasma citri</i>
51-0478	<i>Enterococcus faecalis</i>	51-0231	<i>Staphylococcus aureus</i>
2113-20477	<i>Enterococcus faecium</i>	51-0044	<i>Staphylococcus epidermidis</i>
2114-20160	<i>Enterococcus hirse</i>	2118-20328	<i>Staphylococcus hominis</i>
51-0083	<i>Escherichia coli</i>	2119-20263	<i>Staphylococcus haemolyticus</i>
2115-08579	<i>Escherichia coli</i> O157:H7	2122-20480	<i>Streptococcus equinus</i> (syn. <i>Streptococcus bovis</i> )
51-1368	<i>Fluoribacter bozemaniae</i> (syn. <i>Legionella bozemaniae</i> )	2123-06176	<i>Streptococcus dysgalactiae</i>
2131-05934	<i>Geobacillus stearothermophilus</i>	2126-20523	<i>Streptococcus mutans</i>
2132-30104	<i>Klebsiella pneumoniae</i>	51-0566	<i>Streptococcus pneumoniae</i>
2133-70603	<i>Klebsiella pneumoniae</i> , ESBL+	2139-20068	<i>Streptococcus sanguinis</i>
51-1723	<i>Lactobacillus acidophilus</i>	2120-20229	<i>Staphylococcus saprophyticus</i>
51-1370	<i>Legionella dumoffii</i>	2121-50170	<i>Stenotrophomonas maltophilia</i>
51-1533	<i>Legionella jordanii</i>	51-0177	<i>Ureaplasma urealyticum</i>
51-0101	<i>Legionella pneumophila</i>	2140-04780	<i>Yer sinia enterocolitica</i>
51-1514	<i>Legionella pneumophila</i> subsp. <i>fraseri</i>	2141-08992	<i>Yersinia pseudotuberculosis</i>
51-1515	<i>Legionella pneumophila</i> subsp. <i>pascullei</i>		

### Content

1 vial with genomic DNA extract with 10 ng ± 2 ng, freeze-dried; 1 vial with 200 µl Tris-HCl buffer (10 mM, pH 8.5) for DNA rehydration

Distributed by:

**CliniSciences Group**





# PCR Quantification Standards

## Background & Description

- Conventional and qPCR
- Standard curves, evaluation of assay performance
- Preparation of dilution series for quantification
- Low titer (e.g.  $3 \times \text{LOD}_{95}$ ) controls

Standardization and quantification of nucleic acid detection is a difficult task as there are no reliable standards for low nucleic acid copy numbers. Detection methods such as PCR and NASBA are prone to inhibition caused by many substances commonly found in plant and animal tissues, food matrices and extraction solutions. When co-purified with DNA or RNA, inhibitors reduce amplification efficiency, causing an underestimation of the quantity of target nucleic acid or even false-negative results.

Minerva Biolabs calibration reagents contain genomic DNA extract from low passage and


defined microorganisms. The DNA is extracted by subsequent column absorption methods. The DNA extract was partially sequenced and the sequence aligned to confirm identity. Titration was done after photometric quantification of the preparation standard and dsDNA fluorometric quantification against a synthetic standard.

By using the PCR Quantification Standards, qPCR users can include a precise low count of DNA copies in their assays. This will serve as an exact reference value for the estimation of detection limits and for the comparison between different detection methods.

### Content

1 vial with DNA,  $1 \times 10^8$  genome copies, freeze-dried; 3 vials with 2 ml of Tris-HCl buffer (10 mM, pH 8.5) for rehydration and preparation of serial dilutions

Standard Curve



Real-time Amplification Plot




Fig. Quantification of *Mycoplasma pneumoniae* DNA. Logarithmic plot of fluorescence vs cycle number (Venor®GeM qEP, platform: ABI Prism® 7500). Template DNA ranging from  $2 \times 10^5$  - 2 genome equivalents.

## Ordering Information

### Catalog Number

Cat. No. 52-0116	<i>Acholeplasma laidlawii</i>	Cat. No. 52-0130	<i>Mycoplasma hyorhinae</i>
Cat. No. 52-5571	<i>Bordetella pertussis</i>	Cat. No. 52-0112	<i>Mycoplasma orale</i>
Cat. No. 52-0083	<i>Escherichia coli</i>	Cat. No. 52-0119	<i>Mycoplasma pneumoniae</i>
Cat. No. 52-0101	<i>Legionella pneumophila</i>	Cat. No. 52-0124	<i>Mycoplasma synoviae</i>
Cat. No. 52-0129	<i>Mycoplasma arginini</i>	Cat. No. 52-0164	<i>Spiroplasma citri</i>
Cat. No. 52-0117	<i>Mycoplasma fermentans</i>	Cat. No. 52-0071	<i>Pseudomonas aeruginosa</i>
Cat. No. 52-0115	<i>Mycoplasma gallisepticum</i>	Cat. No. 52-0103	<i>Mycoplasma salivarium</i>

Distributed by:

**CliniSciences Group**



# 10CFU™ Sensitivity Standards

For validating robustness and detection limit of molecular mycoplasma test methods in presence of the sample matrix.

## Background & Description

The *European Pharmacopoeia* (EP 2.6.7), the *Japanese Pharmacopoeia* (JP G3) and the *US Pharmacopoeia* (USP <1071>) define the required sensitivity for nucleic acid-based assays (e.g. PCR) as valid detection methods for microbiological testing of biopharmaceuticals. According to these guidelines, a test sensitivity of 10 colony-forming units (CFU) per ml of sample volume (or min. 100 CFU/ml for USP) must be reached by the performing lab as part of the robustness testing, in presence of the sample matrix.

Each vial of 10CFU™ Sensitivity Standards contains 10 CFU of inactivated mycoplasma, which can be safely and reliably used in cell culture and production facilities, where a microbiology lab is not available. Once resuspended in the sample matrix of interest, these samples must be tested

positive by the applied method. Please note that due to the mycoplasma inactivation, the 10CFU™ Sensitivity Standards are not suitable for the culture method. Extensive proficiency tests indicated that mycoplasma DNA extraction is indispensable to achieve highest sensitivity by PCR-based methods. After extraction, the 10CFU™ extract can directly be used for PCR. The genome units (GU) to CFU ratio is provided in The Certificate of Analysis for each lot.

### Content

Unit package: 3 vials with 10 CFU of the corresponding mycoplasma species; 2 vials with negative controls; Set package (Mycoplasma set Cat. No. 102-0002): 2 vials with 10 CFU of each mycoplasma species listed in the EP 2.6.7 (18 vials in total; *M. salivarium* is not included in the set). 2 vials with negative controls

## Ordering Information

### Catalog Number

Cat. No. 102-8003	<i>Acholeplasma laidlawii</i>	Cat. No. 102-2003	<i>Mycoplasma orale</i>
Cat. No. 102-1003	<i>Mycoplasma arginini</i>	Cat. No. 102-4003	<i>Mycoplasma pneumoniae</i>
Cat. No. 102-6003	<i>Mycoplasma fermentans</i>	Cat. No. 102-5003	<i>Mycoplasma synoviae</i>
Cat. No. 102-3003	<i>Mycoplasma gallisepticum</i>	Cat. No. 102-1103	<i>Mycoplasma salivarium</i>
Cat. No. 102-7003	<i>Mycoplasma hyorhinis</i>	Cat. No. 102-9003	<i>Spiroplasma citri</i>
		Cat. No. 102-0002	Mycoplasma Set

# 100CFU™ Sensitivity Standards

Additional products for validating robustness and detection limit of molecular mycoplasma test methods in presence of a specific sample matrix.

## Background & Description

100CFU™ Sensitivity Standards are designed to support the validation of nucleic acid amplification technology (NAT)-based tests for mycoplasma detection, according to USP <1071>. More generally, including this supplementary concentration in the matrix validation procedure significantly improves the confidence of the test method.

- Irreversibly inactivated mycoplasma in an amount corresponding to 100 CFU.

- Additional test concentration to the 10CFU™ Sensitivity Standards for the validation of PCR-based detection tests.
- The genome units (GU) to CFU ratio is provided in The Certificate of Analysis for each lot.

**Content:** Unit package: 3 vials with 100 CFU of the corresponding mycoplasma species; 2 vials with negative controls

## Ordering Information

### Catalog Number

Cat. No. 103-8003	<i>Acholeplasma laidlawii</i>	Cat. No. 103-2003	<i>Mycoplasma orale</i>
Cat. No. 103-1003	<i>Mycoplasma arginini</i>	Cat. No. 103-4003	<i>Mycoplasma pneumoniae</i>
Cat. No. 103-6003	<i>Mycoplasma fermentans</i>	Cat. No. 103-1103	<i>Mycoplasma salivarium</i>
Cat. No. 103-3003	<i>Mycoplasma gallisepticum</i>	Cat. No. 103-5003	<i>Mycoplasma synoviae</i>
Cat. No. 103-7003	<i>Mycoplasma hyorhinis</i>	Cat. No. 103-9003	<i>Spiroplasma citri</i>

**Distributed by:**

**CliniSciences Group**

# CliniSciences Group

## Austria

Company: CliniSciences GmbH  
Address: Sternwartestrasse 76, A-1180  
Wien - Austria  
Telephone: +43 720 115 580  
Fax: +43 720 115 577  
Email: [oesterreich@clinisciences.com](mailto:oesterreich@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Belgium

Company: CliniSciences S.R.L  
Address: Avenue Stalingrad 52, 1000  
Brussels - Belgium  
Telephone: +32 2 31 50 800  
Fax: +32 2 31 50 801  
Email: [belgium@clinisciences.com](mailto:belgium@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Denmark

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [danmark@clinisciences.com](mailto:danmark@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Finland

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [suomi@clinisciences.com](mailto:suomi@clinisciences.com)  
Web: <https://www.clinisciences.com>



## France

Company: CliniSciences S.A.S  
Address: 74 Rue des Suisses, 92000  
Nanterre - France  
Telephone: +33 9 77 40 09 09  
Fax: +33 9 77 40 10 11  
Email: [info@clinisciences.com](mailto:info@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Germany

Company: Biotrend Chemikalien GmbH  
Address: Wilhelm-Mauser-Str. 41-43,  
50827 Köln - Germany  
Telephone: +49 221 9498 320  
Fax: +49 221 9498 325  
Email: [info@biotrend.com](mailto:info@biotrend.com)  
Web: <https://www.biotrend.com>



## Iceland

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [island@clinisciences.com](mailto:island@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Ireland

Company: CliniSciences Limited  
Address: Ground Floor, 71 lower Baggot street  
Dublin D02 P593 - Ireland  
Telephone: +353 1 6971 146  
Fax: +353 1 6971 147  
Email: [ireland@clinisciences.com](mailto:ireland@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Italy

Company: CliniSciences S.r.l  
Address: Via Maremmana inferiore 378  
Roma 00012 Guidonia Montecelio - Italy  
Telephone: +39 06 94 80 56 71  
Fax: +39 06 94 80 00 21  
Email: [italia@clinisciences.com](mailto:italia@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Netherlands

Company: CliniSciences B.V.  
Address: Kraaijenhoffstraat 137A,  
1018RG Amsterdam, Netherlands  
Telephone: +31 85 2082 351  
Fax: +31 85 2082 353  
Email: [nederland@clinisciences.com](mailto:nederland@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Norway

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [norge@clinisciences.com](mailto:norge@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Poland

Company: CliniSciences sp.Z.o.o.  
Address: ul. Rotmistrza Witolda Pileckiego 67  
lok. 200 - 02-781 Warszawa -Poland  
Telephone: +48 22 307 0535  
Fax: +48 22 307 0532  
Email: [polska@clinisciences.com](mailto:polska@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Portugal

Company: Quimigen Unipessoal LDA  
Address: Rua Almada Negreiros, Lote 5, Loja 14,  
2615-275 Alverca Do Ribatejo - Portugal  
Telephone: +351 30 8808 050  
Fax: +351 30 8808 052  
Email: [info@quimigen.com](mailto:info@quimigen.com)  
Web: <https://www.quimigen.pt>



## Spain

Company: CliniSciences Lab Solutions  
Address: C/ Hermanos del Moral 13  
(Bajo E), 28019, Madrid - Spain  
Telephone: +34 91 269 40 65  
Fax: +34 91 269 40 74  
Email: [espana@clinisciences.com](mailto:espana@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Sweden

Company: CliniSciences ApS  
Address: Oesterbrogade 226, st. 1,  
Copenhagen, 2100 - Denmark  
Telephone: +45 89 888 349  
Fax: +45 89 884 064  
Email: [sverige@clinisciences.com](mailto:sverige@clinisciences.com)  
Web: <https://www.clinisciences.com>



## Switzerland

Company: CliniSciences Limited  
Address: Marktgasse 18 8302 Kloten -  
Switzerland  
Telephone: +41 (044) 805 76 81  
Fax: +41 (044) 805 76 75  
Email: [switzerland@clinisciences.com](mailto:switzerland@clinisciences.com)  
Web: <https://www.clinisciences.com>



## UK

Company: CliniSciences Limited  
Address: 11 Progress Business center, Whittle  
Parkway, SL1 6DQ Slough- United Kingdom  
Telephone: +44 (0)1753 866 511  
or +44 (0) 330 684 0982  
Fax: +44 (0)1753 208 899  
Email: [uk@clinisciences.com](mailto:uk@clinisciences.com)  
Web: <https://www.clinisciences.com>



## USA

Company: Biotrend Chemicals LLC  
Address: c/o Carr Riggs Ingram,  
500 Grand Boulevard, Suite 210 Miramar  
Beach, FL 32550- USA  
Telephone: +1 850 650 7790  
Fax: +1 850 650 4383  
Email: [info@biotrend-usa.com](mailto:info@biotrend-usa.com)  
Web: <https://www.biotrend-usa.com>

